In November Merck paid $588m to LaNova Medicines, another Chinese biotech firm, to secure rights to a therapy similar to that produced by Akeso. China’s government identified biotech as a ...

Thanks to new analytical tools, Chinese herbal medicines are attracting a new burst of R&D activity, as Jane Qiu reports. You have full access to this article via your institution. In the past few ...